Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Review Article Volume 6 Issue 7

Prospects for the Clinical Use of Radionuclide Therapy for Castrate-resistant Metastatic Prostate Cancer with 177Lu-PSMA

Roytberg GE1, Plotkin M2 and Sharkhun OO1*

1Pirogov Russian National Research Medical University, Moscow, Russia
2The Vivantes Institute for Nuclear Medicine, Berlin, Germany

*Corresponding Author: Roytberg GE, Pirogov Russian National Research Medical University, Moscow, Russia.

Received: March 14, 2022; Published: June 20, 2022

Abstract

Despite the improvement of diagnostic methods and the introduction of prostate-specific antigen monitoring, the incidence of advanced forms of prostate cancer in Russia remains high. Long-term hormonal therapy often leads to tumor adaptation and further progression of the disease, the development of castrate-resistant prostate cancer, the complications of which significantly worsen the quality of life and adversely affect overall survival rates. Over the past 3 years along with the introduction into clinical practice of numerous drugs for the treatment of such forms of the disease, new types of palliative peptide receptor radionuclide therapy have been developed in particular, using the isotopes Lutetium-177, Radium-223, Actinium-225 etc. Currently therapy with 177Lu -PSMA is experimental in nature, as the drug has not yet been approved for clinical use by either European or American drug control agencies. However, the results of studies published to date are encouraging for the future clinical applications of 177Lu-PSMA therapy. The results of prospective studies conducted in the last 2-3 years will be crucial for the future of this method.

Keywords: Prostate; Cancer; Radionuclide; Lutetium

References

  1. Freedland SJ., et al. “Treatment patterns in patients with prostate cancer and bone metastasis among US community-based urology group practices”. Urology2 (2012): 293-298.
  2. Tait C., et al. “Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival”. BJU International6b (2014): E70-E73.
  3. Israeli RS., et al. “Expression of the prostate-specific membrane antigen”. Cancer Research7 (1994): 1807-1811.
  4. Benešová M. “Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer”. Journal of Nuclear Medicine 56 (2015): 914-920.
  5. Kratochwil C., et al. “177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer”. European Journal of Nuclear Medicine and Molecular Imaging 42 (2015): 987-988.
  6. Ahmadzadehfar H., et al. “Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study”. EJNMMI Research 5 (2015): 1140259-014-2978-1.
  7. Delker A., et al. “Dosimetry for (177)Lu-DKFZPSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer”. European Journal of Nuclear Medicine and Molecular Imaging 4 (2016): 42-51.
  8. Rahbar K., et al. “German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients”. Journal of Nuclear Medicine 58 (2017): 85-90.
  9. Hofman MS., et al. “TheraP: a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)”. BJU International 124 (2019): 5-13.
  10. Weineisen M., et al. “68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies”. Journal of Nuclear Medicine8 (2015): 1169-1176.
  11. Morris MJ., et al. “Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION)”. ASCO (2021).
  12. de Bono J., et al. “Olaparib for Metastatic Castration-Resistant Prostate Cancer”. The New England Journal of Medicine 22 (2020): 2091-2102.
  13. Kratochwil C., et al. “ (225)Ac-PSMA-617 for Therapy of Prostate Cancer”. Seminars in Nuclear Medicine 2 (2019): 133-140.
  14. Khreish F., et al. “225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience”. European Journal of Nuclear Medicine and Molecular Imaging 3 (2020): 721-728.
  15. S3-Leitlinie Prostatakarzinom (leitlinienprogramm-onkologie.de) Version 6.0 | Mai (2021).
  16. Kratochwil C., et al. “EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)”. European Journal of Nuclear Medicine and Molecular Imaging12 (2019): 2536-2544.
  17. EAU-EANM-ESTRO-ESUR-SIOG-Guidelines-on-Prostate-Cancer-2020 v4.pdf (uroweb.org)
  18. Lowrance WT., et al. “Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II”. Journal of Urology 205 (2021): 22-29.
  19. Khalaf DJ., et al. “Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial”. Lancet Oncology12 (2019): 1730-1739.

Citation

Citation: Roytberg GE., et al. “Prospects for the Clinical Use of Radionuclide Therapy for Castrate-resistant Metastatic Prostate Cancer with 177Lu-PSMA”.Acta Scientific Medical Sciences 6.7 (2022): 179-183.

Copyright

Copyright: © 2022 Roytberg GE., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In





News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is November 30, 2022.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US